Morrison Foerster is an international law firm with lawyers practicing throughout the United States, Asia, and Europe. Click to discover more.

mofo_share_image.jpg

Morrison Foerster

common-default.jpeg

Terms / Notices

Cookies

Privacy Policy

Reporting Hotline

Attorney Advertising

Alumni

  Linkedin

MoFo LinkedIN

  Facebook

MoFo Facebook

YouTube

MoFo Youtube

Morrison Foerster - Footer

Morrison & Foerster Advises Tate & Lyle PLC on Acquisition of Stevia Sweetener Solutions Business Sweet Green Fields

You have not solved the recaptcha challenge yet or session expired, try again.

Email Disclaimer

Disclaimer

Unsolicited e-mails and information sent to Morrison Foerster will not be considered confidential, may be disclosed to others pursuant to our <a href="https://www.mofo.com/about/privacy-policy.html">Privacy Policy</a>, may not receive a response, and do not create an attorney-client relationship with Morrison Foerster. If you are not already a client of Morrison Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.

Feedback

mofo-logo-2022.svg

People

Capabilities

Resources

About

Culture

Offices

Careers

Stay Connected

Morrison & Foerster advised LSE-listed Tate & Lyle PLC (Tate & Lyle), a leading global provider of food and beverage ingredients and solutions, on its acquisition of Sweet Green Fields (SGF), a leading global stevia solutions business.

About Morrison Foerster

people-default-header-desktop.jpg

people-default-header-mobile.jpg

Default Meta Data

Morrison & Foerster advised LSE-listed Tate & Lyle PLC (Tate & Lyle), a leading global provider of food and beverage ingredients and solutions, on its acquisition of Sweet Green Fields (SGF), a leading global stevia solutions business.The acquisition strengthens Tate & Lyle’s position as a leading provider of innovative sweetener solutions with the capabilities to create foods and beverages that are lower in sugar and calories and with cleaner labels for customers around the world. The acquisition also extends Tate & Lyle’s presence in the rapidly developing Asia Pacific region with dedicated stevia production and research and development facilities located in Anji, China.The transaction was announced on December 1, 2020.Morrison & Foerster is widely recognized as one of the world’s leading law firms for food, agriculture, and ag-tech M&A transactions, including being “Top Ranked” in the space by legal directory Chambers Global.The MoFo deal team was led by London Corporate partner Andrew Boyd. The global deal team included Shanghai Corporate partner Chuan Sun; Hong Kong Tax partner Matthew Lau; Boston Corporate associate Leo Martin; San Francisco Corporate associates Amy Chen and Olga Terets; London Corporate associates Patrick Barrett and Nishita Vasan; Shanghai Corporate associates Tian Zhou and Sarah Wang, and Corporate consultant Huijun Zhang; Beijing Corporate senior consultant Xuezi Dan; and Hong Kong Corporate of counsel Catherine Liu and associates Katrina Tsoi and Julia Lee.Read more about the transaction in Tate & Lyle’s <a target="_blank" href="https://www.tateandlyle.com/news/tate-lyle-acquires-sweet-green-fields">press release</a>.

Morrison & Foerster Advises Tate & Lyle PLC on Acquisition of Stevia Sweetener Solutions Business Sweet Green Fields

Sign Up

Andrew Boyd is an M&A partner based in the London office. He specializes in advising on strategic cross-border mergers and acquisitions, private equity and joint venture transactions with particular expertise advising clients in the technology and food/ag sectors.Andrew regularly represents, among other clients, Uber, Visa, SoftBank, Tate & Lyle plc, Unity Technologies, Toshiba and SoundCloud.Andrew is recommended for M&A and private equity by legal directories including Legal 500 and IFLR1000 and is noted for his ability to “speedily assimilate difficult concepts and come up with meaningful, deliverable action plans that fulfil the commercial objectives”. Clients note that “Andrew knows exactly when and where to get involved …a good person to send in when we need a different voice…he gets to the nub of the issue very, very quickly and with great clarity…” and “Andrew Boyd is fantastic; pragmatic, tons of expertise, and a joy to work with.” Legal 500 2022.Andrew is co-Managing Partner of the London office and sits on the firm’s global Partnership Selection committee and was previously a member of the firm’s global Pro Bono committee.

Andrew Boyd

Managing Partner, London

Chuan focuses his practice on cross-border M&A transactions; sophisticated technology, media, and telecom (TMT) transactions; and complex IP/commercial matters across Greater China.With 19 years of experience in both Asia and the U.S., Chuan regularly advises multinational corporations, state-owned enterprises, private companies, and PE/VC firms in complex cross-border M&A transactions, joint ventures, strategic alliances, and business separation transactions.Chuan also has significant experience in strategic corporate-commercial and technology transactions, including outsourcing, manufacturing, distribution, supply and franchising arrangements, and IP licensing arrangements across multiple industries. His TMT and IP regulatory experience includes telecommunications, e-commerce, internet, cyber security, data privacy, cloud computing, as well as telematics.Prior to joining MoFo, he worked in the Hong Kong office of a Magic Circle firm and the Chicago office of another leading international firm.Chuan co-authored the Hong Kong & mainland China chapters of Getting the Deal Through – Telecoms and Media, 2014, 2015 & 2016; the Hong Kong & mainland China chapters of Getting the Deal Through: Market Intelligence – Telecoms and Media, 2015; and the Hong Kong chapter of Sourcing World 2nd Edition 2015.Chuan is fluent in Mandarin and English.“Chuan Sun has a wealth of knowledge on his clients’ existing products and services offerings and a good understanding of what terms they are or are not willing to accept. This helps tremendously with contract negotiations.”“Chuan Sun has extensive experience in the technology space. Many other competitor firms in the technology space are not really pure IT lawyers, as they are more focus on privacy and trade marks or other related fields, as opposed to technology contracts such as SAP or Microsoft software license agreements. A normal general commercial lawyer would not be able to identify the same issues or raise the right questions, as they are not equipped with the technology know-how of the products and services, their benefits, and general industry standard terms and trending patterns in the market.” Legal 500 Asia Pacific 2020

孙川律师的执业领域集中在大中华区的跨境并购交易，复杂的技术、媒体和电信(TMT)交易以及复杂的知识产权/商务事宜。孙律师在亚洲和美国有19年工作经验，他经常代理跨国公司、国有企业、私人企业和私募股权/风险投资机构处理复杂的跨境并购交易、合资、战略联盟和业务拆分等交易。孙律师在战略性的公司商务和技术交易方面也拥有极为丰富的经验，包括外包、制造、分销、供应与特许经营安排，以及跨行业知识产权许可安排等。他在TMT和知识产权监管方面的经验包括电信、电子商务、互联网、网络安全、数据隐私、云计算以及车联网。在加入美富前，孙律师在一家 “魔法圈”律所(Magic Circle)的香港办事处和另一家领先的国际律所的芝加哥办事处工作。孙律师与他人合著了2014，2015和2016版《让交易推进下去––电信与媒体》(Getting the Deal Through – Telecoms and Media)中的香港和中国大陆章节，2015年版《让交易推进下去：市场情报––电信与媒体》(Getting the Deal Through: Market Intelligence – Telecoms and Media)中的香港和中国大陆章节，以及2015年《采购世界》第二版(Sourcing World 2nd Edition)的香港章节。2018年《亚太法律500强》指出“孙川律师十分高效、负责和实际。他非常擅长处理IT协议，包括软件许可和IT采购合同的相关事宜。他也十分善于处理跨境TMT交易。”孙律师精通普通话和英语。

Chuan Sun

Managing Partner, Shanghai

Matthew’s practice focuses on the tax structuring of cross–border M&A transactions and corporate reorganizations, particularly involving the United States, China, Japan, and the rest of the Asia–Pacific region. He also regularly advises U.S. and Asia–based fund sponsors and institutional investors on tax issues related to the formation of, and investments in, private equity funds, venture capital funds, real estate funds, and other co–investment vehicles and alternative investment products.Matthew also has extensive experience advising leading insurers on warranty and indemnity policies for M&A transactions in Asia and the United States. He has represented multinational corporations and funds in transactions across more than 30 jurisdictions. Matthew advises clients from a wide range of industries, including consumer, energy, health care, media, natural resources, real estate, technology, and telecommunications.Matthew is a Registered Foreign Lawyer with the Law Society of Hong Kong.While at Columbia Law School, Matthew was a three–year Harlan Fiske Stone Scholar.

刘恩安 (Matthew Lau) 律师的业务重点为跨境并购交易和公司重组的税务规划，特别是在美国、中国、日本以及其他亚太地区的相关业务。他还经常就设立和投资私募股权基金、风险投资基金、房地产基金、其他联合投资工具和另类投资产品所涉及的税务问题，向美国和亚洲的基金发起人和机构投资者提供咨询。刘律师在代表领先的保险公司处理亚洲和美国的并购交易的保证和赔偿政策方面也拥有丰富的经验。他曾代表多家跨国公司和基金在30多个司法管辖区处理交易。刘律师的客户涉及多个行业，包括消费品、能源、医疗保健、传媒、天然资源、房地产、科技和电讯等。刘律师是香港律师会注册外地律师。在哥伦比亚大学法学院就读期间，刘律师连续三年获得哈伦•菲斯克•斯通奖学金。

Matthew Lau

Partner

Leo Martin is a corporate partner in the Transactions Department and the Mergers + Acquisitions Group, based in the firm’s Boston office.His practice focuses on advising public and private companies in complex corporate transactions, including domestic and cross-border M&A, carve-out transactions, venture investments, and joint ventures. He regularly represents private equity sponsors and clients in a range of industries, including technology, food + agriculture, financial services, manufacturing, and consumer products.Leo earned his J.D. from Fordham University School of Law and his B.A. from Columbia College at Columbia University. Prior to joining the firm’s Boston office, Leo spent a number of years in Morrison Foerster’s Tokyo office, where he worked on a variety of cross-border M&A transactions.

Leo Martin

Amy advises on corporate and transactional matters with a special focus on domestic and cross-border mergers and acquisitions, joint ventures and other corporate transactions.Her clients have included U.S. and global public and private companies in a wide range of industries including technology, financial services, consumer products, healthcare, life sciences, insurance and private equity. She has worked on a number of complex cross-border transactions in the UK, Europe, Asia and Australia.Prior to joining Morrison Foerster, Amy was Senior Legal Counsel at MILVIK BIMA, a fintech provider of micro-insurance and telehealth solutions, where she helped them navigate the complex regulatory landscapes of emerging markets across Asia, Africa and Latin America. She also served as Senior Legal Counsel at Aviva plc in London, where she advised on a range of corporate and M&A matters, and supported their corporate venture fund focused on technology investments.Amy was also previously a corporate associate at another international law firm in London, where she advised on corporate and cross-border M&A matters.She earned her law degree at the University of Sydney in Australia, and is qualified as an attorney in New York and a solicitor in England & Wales.

Amy Chen

Associate

Sarah frequently advises clients in strategic corporate-commercial and technology transactions in the sectors of life science and TMT, including in-licensing, out-licensing, collaboration, and development agreements in various types of traditional and emerging technology offerings, including software-as-a-service, on-premises software, and technology services and maintenance, and in a broad range of pharmaceutical products and technologies, including biopharmaceutical drugs, immunotherapies, antibody therapeutics, and vaccines.Before joining MoFo, Sarah was an associate in the Shanghai office of an international law firm. She is fluent in English and Mandarin.<h4>Representative Experience</h4><ul><li>A leading healthcare investment firm’s portfolio company in its series of license-in and license-out deals concerning: (i) the development and option agreement and license agreement with a private biotechnological company in the North America for the development of lipid nanoparticles (LNP) formulations for delivery of mRNA and for the commercialization and manufacturing of the protein product and the vaccine product utilizing the LNP technology; and (ii) the licensing-out agreement with a Hong Kong listed company for the development and commercialization of the mRNA technology in Greater China.</li></ul><ul><li>Hangzhou DAC Biotechnology Co., Ltd. on its collaboration and license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for the development and commercialization of antibody drug conjugate (ADC) products.</li><li>Jiangsu Hengrui Medicine Co., Ltd. in its US$165 million exclusive license agreement with Novaliq GmbH, a German pharmaceutical company focusing on ocular therapeutics, to develop, manufacture and commercialize the innovative, water-free drugs NOV03 (perfluorohexyloctane) and CyclASol® for the treatment of dry eye disease in mainland China, Hong Kong, Macau and Taiwan.</li><li>A FinTech firm in the strategic partnership between a pan-Asia retailer and a Hong Kong bank to construct a new customer loyalty and reward program to replace the current co-branded credit card program on the market.</li><li>An automobile retailer that is a subsidiary of a multi-national dealership operator in its ERP software license and support agreement and the service agreement with a European multi-national software corporation, on the subscription of its core software products and technologies.</li></ul>

王家尧律师经常就生命科学以及科技、媒体和电信（TMT）领域战略性的公司商业交易和技术交易向客户提供咨询，包括协助客户编制被许可协议、对外许可协议、协作协议及开发协议，涉及各种传统及新兴技术产品和服务，包括软件即服务（SaaS）、本地部署软件以及技术服务和维护等，还涉及广泛的医药产品和技术，包括生物制药产品、免疫疗法、抗体疗法和疫苗等。在加入美富前，王律师是一家国际律所上海办事处的律师。她精通英语和普通话。<h4>具有代表性的项目 </h4><ul><li>代表某顶级医疗保健投资机构的被投资公司处理涉及下列事宜的系列被许可及对外许可交易：（1）代表某领先的生物医药公司就其与加拿大某生物公司签订开发和选择权协议以及对内许可协议提供法律服务，以开发用于传递mRNA的脂质纳米颗粒（LNP）配方，并对利用LNP技术的蛋白质产品和疫苗产品进行商业化和生产；以及（2）与某香港上市公司签订对外许可协议，以在大中华区对mRNA技术进行开发和商业化。</li></ul><ul><li>代表杭州多禧生物科技有限公司与强生公司旗下杨森制药生物科技公司达成合作和许可协议，用于抗体偶联药物（ADC药物）的开发与商业化。</li></ul><ul><li> 代表江苏恒瑞医药股份有限公司处理其与Novaliq GmbH（一家专注于眼部治疗的德国制药公司）的1.65亿美元独家许可协议，对创新型无水药物NOV03（全氟己内酯）和CyclASol®进行开发、生产和商业化，用于在中国大陆、香港、澳门和台湾地区治疗干眼症。</li></ul><ul><li> 代表一家金融科技公司处理其所属的泛亚洲零售商与一家香港银行的策略性合伙，订立新的老顾客奖励计划来取代目前市场上的联合品牌信用卡计划。</li></ul><ul><li> 代表一家国际汽车经销集团旗下的汽车零售商，处理其ERP软件许可证和支持协议及与一家欧洲国际软件公司的服务协议，以订阅模式付费使用其核心软件产品和技术。</li></ul>

Sarah Wang

Katrina’s practice focuses on a diverse range of corporate matters, including cross-border mergers and acquisitions, private equity investments, regulatory and compliance, and other general corporate matters.Katrina has experience advising multinational companies, sovereign wealth funds, private equity investors, family offices, and start up entrepreneurs across various sectors including consumer goods and services, life sciences, and technology (including AgTech).Katrina is fluent in English, Cantonese and Mandarin.<h4>Representative Matters</h4><ul><li>Happiness Capital</li><ul><li>in its US$350,000 Series Seed investment in Kyomei, a company with innovative molecular farming technology to use plants to produce animal-identical proteins that replicate the taste and nutritional value of traditional meat.</li><li>in connection with the US$10 million Series A minority investment in Botrista, a U.S.-based robotic barista automation solution provider.</li><li>in connection with the US$4.7 million equity investment in NovoNutrients, a U.S.-based alternative proteins company that transforms CO2 emissions into high-value, low-cost proteins and additives for food and feed.</li></ul><li>Cayman Islands-incorporated and Taiwan-based The News Lens Co., Ltd. (TNL) in its proposed de-SPAC with Blue Ocean Acquisition Corporation (NASDAQ: BOCN), a publicly traded special purpose acquisition company, and its proposed listing on NASDAQ.  TNL is an independently owned international web media group with editions of its core “The News Lens” brand published in Taiwan, Hong Kong, ASEAN and Japan as well as an International (English) edition. </li><li>Ally Bridge Group in connection with numerous investments in various life sciences companies, including: </li><ul><li>as lead investor in connection with the US$60 million Series F financing of Aerin Medical Inc., a medical technology company focused on the ear, nose and throat market providing non-invasive solutions for the treatment of chronic nasal conditions.</li><li>as lead investor in connection with the US$62 million Series D financing of Mission Bio, Inc., a life science tools company focused on single cell genomics, proteomics and multi-omics solutions for oncology study and cell and gene therapy development.</li><li>as lead investor in connection with the $101 million Series B financing of Endeavor BioMedicines, a clinical-stage biotechnology company targeting the core drivers of terminal diseases including oncology and fibrosis.</li><li>as lead investor in connection with an oversubscribed US$265 Million Series B financing of Sonoma Biotherapeutics, a U.S. based life sciences company developing treatments for autoimmune and degenerative disease.</li><li>in the follow-on US$100 million Series D financing of a company with a subscription-based application that connects patients with professional health coaches, nutritionists, exercise physiologists, nurses, and diabetes educators. </li><li>in a follow-on US$81 million equity investment in Rapid Micro Biosystems, Inc., a U.S. based medical product manufacturer. Including this latest financing, Rapid Micro Biosystems has raised over $340 million of equity for its expansion.</li><li>in connection with the $200 million Series C investment of Transcarent, a new and different health and care experience company for employees of self-insured employers and their families.</li></ul><li>LeapXpert, a Hong Kong and US-based communications and messaging platform provider, in connection with its US$22 million Series A+ financing led by Rockefeller Asset Management. The investment also includes participation from Uncorrelated Ventures, the Partnership Fund for New York City, and a new strategic investor, as well as existing investors.</li></ul><ul><li>Tencent Holdings Limited its US$46 million (JPY5 billion) acquisition of a majority stake in Wake Up Interactive Limited, together with its wholly-owned subsidiaries in Japan, Valhalla Game Studios Ltd. and Soleil Ltd., which produce video games and online entertainment. </li><li>LSE-listed Tate & Lyle PLC, a leading global provider of food and beverage ingredients and solutions,<ul><li>in connection with its agreement to acquire Quantum Hi-Tech (Guangdong) Biological Co., Ltd, a leading prebiotic dietary fiber business in China, from ChemPartner Pharmatech Co., Ltd.</li><li>on its acquisition of Sweet Green Fields (SGF), a leading global stevia solutions business.</li></ul></li><li>Ping An Insurance (Group) Company of China Ltd. in its capital and strategic alliance with Shionogi & Co., Ltd. with a total value of US$780 million, which includes (i) subscription of a 2.05% voting stake in Shionogi and (ii) establishment of joint ventures in Shanghai and Hong Kong. Shionogi is a leading research-driven pharmaceutical company headquartered in Japan.</li><li>Ascendent Automation (Cayman) Limited, an affiliate of Ascendent Capital Partners as one of the Joint Offerors, in its offer to privatize China Automation Group Limited (CAG) (0569.HK) by way of a Cayman scheme of arrangement for HK$391,998,649.50 (about US$50.06 million). Ascendent Capital Partners also provided a loan facility to the other joint offeror (being the controlling shareholder of CAG) for the purpose of the offer. CAG is a China-based company principally engaged in: (i) the provision of safety and critical control system and control valves specialized for petrochemical industries, along with related maintenance and engineering services; and (ii) hospital business in Suzhou, the PRC.</li><li>SoftBank Vision Fund in connection with an investment totaling US$1.5 billion in Chehaoduo, a leading Chinese customer-to-customer auto retail services company that operates Guazi, an e-commerce platform focusing on second-hand car transactions, and Maodou, an e-commerce platform focusing on new car transactions.</li></ul>

蔡嘉莉律师的执业领域侧重于各类公司事宜，包括跨境并购、私募股权投资、监管与合规，以及其他一般公司事宜。蔡律师在为跨国公司、主权财富基金、私募股权投资者、家族办公室和初创企业家提供法律意见方面经验丰富，客户涉及消费品和服务、生命科学和技术（包括农业技术）等多个领域。蔡律师精通英语、粤语和普通话。<h4>具有代表性的交易</h4><ul><li>代表Happiness Capital 处理一系列投融资事宜，包括</li></ul><ul><li>处理其对 Kyomei 公司进行的 35万美元的种子轮投资事宜，该公司拥有创新的分子农业技术，可利用植物生产与动物相同的蛋白质，从而复制传统肉类的味道和营养价值。</li><li>处理对Botrista的A轮与B轮股权投资事宜。Botrista是一家位于美国的为混合饮料提供自动化解决方案的跨国机器人公司。</li><li>处理对NovoNutrients的470万美元股权投资事宜。NovoNutrients是美国一家替代蛋白公司，可将二氧化碳排放物转化为高价值、低成本的蛋白质及食品和饲料添加剂。</li></ul><ul><li>代表在开曼群岛注册、总部设在台湾的The News Lens Co., Ltd. (TNL)处理其与纳斯达克上市的特殊目的收购公司Blue Ocean Acquisition Corporation (NASDAQ: BOCN) 的合并以及其在纳斯达克上市的事宜。TNL是一家独立的国际网络媒体集团，其核心品牌“关键评论网“( "The News Lens ")在台湾、香港、东盟和日本运营，并拥有国际英文版。</li><li>代表软银集团公司和软银愿景基金处理其拟以650亿美元将Arm Limited出售给美国领先的芯片公司NVIDIA（纳斯达克股票代码：NVDA）的事宜。Arm Limited是一家总部位于英国的跨国半导体和软件设计公司。</li></ul><ul><li>代表汇桥资本处理一系列投融资事宜，包括</li><ul><li>作为牵头投资人处理其对Aerin Medical Inc.规模为6000 万美元的F轮融资事宜。Aerin Medical是一家专注于耳鼻喉市场的医疗技术公司，为慢性鼻腔疾病的治疗提供非侵入性解决方案。</li><li>作为牵头投资人处理其对Mission Bio Inc.规模为6200 万美元的D轮融资事宜。Mission Bio是一家生命科学工具公司，专注于单细胞基因组学、蛋白质组学和多组学解决方案肿瘤学研究以及细胞和基因疗法。</li><li>作为牵头投资者处理Endeavor BioMdicines的01亿美元B轮融资事宜。Endeavor BioMedicines是一家处于临床阶段的生物技术公司，主要针对肿瘤和纤维化等绝症的核心驱动因素。</li><li>作为领投方处理Sonoma Biotherapeutics获超额认购的65亿美元B轮融资事宜。该公司是一家美国生物科技公司，致力于开发自体免疫性和退行性疾病的治疗方法。</li><li>处理一家基于订购的虚拟医疗保健公司的后续1亿美元D轮融资事宜。该公司将患者与专业的健康教练、营养师、运动生理学家、护士和糖尿病教育者联系起来。</li><li>处理美国医疗产品制造商Rapid Micro Biosystems, Inc.的8100万美元后续股权投资事宜。包括此次最新轮融资在内，Rapid Micro Biosystems已经为其扩张筹集了超过4亿美元。</li><li>处理Transcarent公司的2亿美元C轮投资事宜。Transcarent面向自保雇主的雇员及其家人提供新型且与众不同的健康和护理体验。</li></ul></ul><ul><li>代表总部位于香港和美国的通信和信息平台供应商LeapXpert就其$2200万美元的A+轮融资提供咨询服务，该轮融资由洛克菲勒资产管理公司(Rockefeller Asset Management)牵头。该项投资的参与者还包括Uncorrelated Ventures、纽约市合伙基金和一名新的战略投资者，以及现有投资者。</li></ul><ul><li>代表腾讯处理其以 4600 万美元（50 亿日元）收购 Wake Up Interactive Limited 及其在日全资子公司 Valhalla Game Studios Ltd. 和 Soleil Ltd. 的多数股权事宜。Wake Up Interactive是日本一家创意游戏公司，从事视频游戏和网络游戏开发。 </li></ul><ul><li>代表在伦敦证券交易所上市的领先的全球食品和饮料原料及解决方案提供商泰莱集团(Tate & Lyle PLC)</li><ul><li>处理其从睿智医药股份有限公司协议收购其旗下量子高科（广东）生物有限公司的事宜。</li><li>处理其收购领先的全球甜菊糖供应商Sweet Green Fields (SGF)的事宜。</li></ul></ul><ul><li>代表中国平安保险（集团）股份有限公司处理其与盐野义制药株式会社高达7.8亿美元的资本与战略联盟的事宜，当中涉及(i) 认购盐野义的2.05%具表决权股份，及(ii) 于上海及香港分别设立合资公司。盐野义为一家总部设于日本的领先的研究型医药公司。</li><li>代表Ascendent Automation (Cayman) Limited（上达资本的全资子公司）作为联合要约人之一处理其对中国自动化集团有限公司（香港股份代号：0569）规模为391,998,649.50港元（约5,006万美元）的私有化安排。上达资本还为作为中国自动化集团有限公司控股股东的联合要约人提供贷款。中国自动化集团是一家总部位于中国的公司，主要从事的业务包括：（i）提供专门用于石化行业的安全及紧急控制系统及安全阀，以及相关之保养及工程服务；（ii）位于中国苏州的医院相关业务。</li><li>代表软银愿景基金处理其对车好多集团总计15亿美元的投资。车好多是中国领先的汽车直卖平台，旗下主要包含瓜子二手车直卖网（主要经营二手车交易）和毛豆新车网（主要经营新车交易）两大平台。</li></ul>

Katrina Tsoi

Julia’s practice spans across cross-border M&A, joint ventures, as well as private equity.Prior to joining Morrison & Foerster, Julia was an associate in the Hong Kong office of a major international law firm.Julia is fluent in English, Cantonese, and Mandarin.

李恺宜律师业务涵盖跨境并购、合资公司及私募股权。在加入美富前，李律师曾在某领先的国际法律事务所的香港办事处担任律师。李律师精通英语、粤语及普通话。